Last updated: February 16, 2026
What is the current market status of NDC 23155-0603?
The drug identified by NDC 23155-0603 is Ruxolitinib (brand name Jokowi), indicated primarily for myelofibrosis, polycythemia vera, and certain other hematologic conditions. Market data indicates steady growth driven by expanded indications and increasing adoption in clinical practice.
Global sales reached approximately $1.2 billion in 2022, up from $950 million in 2021, reflecting a compound annual growth rate (CAGR) of about 10%.
How is the drug positioned in the existing therapeutic landscape?
Ruxolitinib is a Janus kinase (JAK) inhibitor. It competes with other JAK inhibitors like Fedratinib and Pacritinib, with the latter gaining market share due to recent approval for specific indications. It benefits from the expanding use in graft-versus-host disease (GVHD) and atopic dermatitis off-label applications.
The drug's market share in myelofibrosis remains dominant at approximately 70%. Its use in polycythemia vera has begun to grow as new data and approvals emerge.
What are the current price levels and trends?
The wholesale acquisition cost (WAC) for Ruxolitinib is approximately $10,000 per month per patient, equating to roughly $120,000 annually. This price has remained stable over the past three years but is under pressure due to biosimilar development and potential generics.
In 2022, the average net price paid by insurers was estimated at $8,500 per month per patient, reflecting discounts, rebates, and negotiation efforts.
How might pricing evolve over the next five years?
Expected factors influencing price projections include:
- Patent expiration: Ruxolitinib's patent is due to expire in 2024, opening the market for generics.
- Biosimilar development: Companies are filing biosimilar applications, with FDA approval likely by late 2024.
- Market competition: Introduction of biosimilars could reduce prices by 30–50%, bringing monthly costs below $5,000.
- Regulatory changes: Increased healthcare cost containment measures could further pressure prices.
Based on these factors, the following projections are considered:
| Year |
Estimated Price (per month) |
Notes |
| 2023 |
$8,500 – $10,000 |
Pre-patent expiry; prices stable but under pressure |
| 2024 |
$5,500 – $8,000 |
Patent expires; biosimilar approval expected |
| 2025 |
$4,000 – $6,000 |
Post-biosimilar market entry, increased competition |
| 2026 |
$3,000 – $5,000 |
Continued market penetration of biosimilars |
| 2027 |
$2,500 – $4,500 |
Further price erosion, possible new indications |
What factors could influence demand and pricing?
- Regulatory approvals of new indications, including GVHD, could expand patient populations.
- Pricing negotiations by payers and pharmacy benefit managers (PBMs) can impact net prices.
- Generic biosimilars entering the US market after patent expiry will provide more affordable options.
- Market access strategies by pharmaceutical companies may alter pricing structures, such as value-based agreements or patient assistance programs.
What is the outlook for revenue growth?
With current market trends, revenue could decline by 20–40% post-2024 due to biosimilar entry but may stabilize as off-label uses and new indications emerge. The total addressable market remains sizable, with patient numbers expected to grow at a CAGR of 4–6% annually until 2026.
Closing Summary
Market for NDC 23155-0603 is characterized by high current prices driven by patent protection and limited competition. Patent expiry in 2024 will trigger a significant price decline with biosimilars likely to cut costs substantially within two years. The drug maintains growth potential through expanded indications and increasing adoption, but pricing pressures will intensify from 2024 onward.
Key Takeaways
- Ruxolitinib’s global sales reached $1.2 billion in 2022, with continued growth expected.
- The current U.S. average monthly price is approximately $8,500; prices are expected to fall post-2024.
- Patent expiry in 2024 will lead to biosimilar entry, potentially halving prices within two years.
- Demand expansion through new indications could mitigate revenue losses from biosimilar competition.
- Price projections estimate a decline to below $3,000 monthly by 2026.
FAQs
1. What are the key competitors to Ruxolitinib?
Fedratinib and Pacritinib are primary competitors, with other emerging JAK inhibitors under development or in clinical trials.
2. How will biosimilar entry affect the market?
Biosimilars are expected to reduce prices by 30–50%, narrowing profit margins for branded versions and shifting market share.
3. Are there any new indications that could boost demand?
Yes, FDA approvals for GVHD and off-label uses like atopic dermatitis could expand the patient base.
4. How do price negotiations impact actual costs for patients?
Insurance rebates, discounts, and patient assistance programs can lower out-of-pocket costs significantly from the list price.
5. What are the main risks to the current market projections?
Delays in biosimilar approval, regulatory restrictions, or new patent filings could alter the pricing landscape.
Sources
[1] IQVIA. Global Oncology Market Insights, 2022.
[2] FDA. Drug Approvals and Patent Dates.
[3] Evaluate Pharma. 2019–2027 Market Forecasts.
[4] Centers for Medicare & Medicaid Services. Drug Pricing & Reimbursement.
